A series of Ketamine infusion treatments for chronic pain have sprouted “Ketamine Clinics” globally but the longer outcome has not clearly been defined. Ketamine as an opioid-avoiding modality has often spurred the movement.
This review and meta-analysis summarizes the data, finding benefit in the short term (a few weeks) with less confidence on longer term pain relief, as well as higher incidences of nausea and psychotomimetic side effects:
“Evidence suggests that IV ketamine provides significant short-term analgesic benefit in patients with refractory chronic pain, with some evidence of a dose–response relationship. Larger, multicenter studies with longer follow-ups are needed to better select patients and determine the optimal treatment protocol.”